Edition:
United Kingdom

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

12.01USD
20 Apr 2018
Change (% chg)

$1.82 (+17.86%)
Prev Close
$10.19
Open
$10.19
Day's High
$14.68
Day's Low
$9.90
Volume
1,103,678
Avg. Vol
124,250
52-wk High
$14.99
52-wk Low
$2.69

Latest Key Developments (Source: Significant Developments)

Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals
Friday, 20 Apr 2018 

April 20 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM REACHES SETTLEMENT AGREEMENT WITH DICERNA PHARMACEUTICALS RESOLVING TRADE SECRET MISAPPROPRIATION AND OTHER PENDING LITIGATION.ALNYLAM PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, DICERNA WILL PAY $25 MILLION COMPRISED OF CASH AND STOCK TO ALNYLAM.ALNYLAM PHARMACEUTICALS INC - SETTLEMENT DOES NOT INCLUDE ANY LICENSE TO ALNYLAM'S GALNAC CONJUGATE INTELLECTUAL PROPERTY.ALNYLAM - AS PER SETTLEMENT, DICERNA WILL BE RESTRICTED IN ITS DEVELOPMENT RELATING TO OLIGONUCLEOTIDE-BASED THERAPEUTICS FOR A DEFINED SET OF CO'S TARGETS.ALNYLAM PHARMACEUTICALS - ALL OTHER SETTLEMENT TERMS ARE CONFIDENTIAL.  Full Article

Dicerna Pharma Files ‍Prospectus Related To Offering
Monday, 19 Mar 2018 

March 19 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA PHARMACEUTICALS INC FILES ‍PROSPECTUS RELATED TO OFFERING UP TO 24.5 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING​.  Full Article

Ecor1 Capital Llc Reports a 9.4 Percent Passive Stake In Dicerna Pharmaceuticals
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Dicerna Pharmaceuticals Inc ::ECOR1 CAPITAL, LLC REPORTS A 9.4 PERCENT PASSIVE STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 20, 2017.  Full Article

RA Capital Management LLC Reports 9.9 Pct Stake In Dicerna Pharmaceuticals
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Dicerna Pharmaceuticals Inc ::RA CAPITAL MANAGEMENT LLC REPORTS 9.9 PERCENT STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 18 - SEC FILING.RA CAPITAL MANAGEMENT LLC PREVIOUSLY REPORTED 19.9 PERCENT STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 13.RA CAPITAL MANAGEMENT -ON DEC 18,ALL DICERNA PHARMA SHARES OF REDEEMABLE CONVERTIBLE PREFERRED STOCK HELD BY RA CAPITAL WERE CONVERTED INTO COMMON STOCK.  Full Article

Bain Capital Life Sciences Fund Reports 15.7 Percent Stake In Dicerna Pharmaceuticals
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Bain Capital Life Sciences Fund L.P::BAIN CAPITAL LIFE SCIENCES FUND L.P. REPORTS 15.7 PERCENT STAKE IN DICERNA PHARMACEUTICALS INC AS ON DEC 18 - SEC FILING.BAIN CAPITAL LIFE SCIENCES FUND L.P. HAD PREVIOUSLY REPORTED 26.4 PERCENT STAKE IN DICERNA PHARMACEUTICALS INC AS ON SEPT 15.BAIN CAPITAL LIFE SCIENCES-ON DEC 18,ALL DICERNA PHARMA SHARES OF REDEEMABLE CONVERTIBLE PREFERRED STOCK HELD BY BAIN WERE CONVERTED INTO COMMON STOCK.  Full Article

Dicerna Announces Pricing Of Follow-On Public Offering Of Common Stock
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES PRICING OF FOLLOW-ON PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.71 MILLION COMMON SHARES PRICED AT $7.00PER SHARE.  Full Article

Dicerna Pharmaceuticals Files Preliminary Prospectus Supplement Related To A Potential Common Stock Offering
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA PHARMACEUTICALS INC FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL COMMON STOCK OFFERING - SEC FILING.  Full Article

Dicerna announces proposed public offering of common stock
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.DICERNA PHARMACEUTICALS INC - TO USE PROCEEDS FROM OFFERING FOR PRECLINICAL STUDIES & CLINICAL TRIALS.  Full Article

Dicerna Announces First Human Dosed In Phase 1 Clinical Trial Of DCR-PHXC
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES FIRST HUMAN DOSED IN PHASE 1 CLINICAL TRIAL OF DCR-PHXC FOR TREATMENT OF ALL FORMS OF PRIMARY HYPEROXALURIA.DICERNA PHARMACEUTICALS - ANTICIPATES THAT HUMAN PROOF-OF-CONCEPT DATA FROM PHASE 1 TRIAL FOR DCR-PHXC WILL BE AVAILABLE IN SECOND HALF OF 2018.  Full Article

Dicerna Pharmaceuticals Q3 loss per share ‍$0.92
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Dicerna Pharmaceuticals Inc :Q3 2017 loss per share ‍$0.92.  Full Article

UPDATE 2-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.